106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2020 All rights reserved
Disclaimer
is pocket guide is derived om recommendations in the American Society of Clinical Oncolog y
Guideline. is resource is a practice tool based on ASCO
®
practice guidelines and is not intended
to substitute for the independent professional judgment of the treating physician. Practice guidelines do
not account for individual variation among patients. is pocket guide does not purport to suggest any
particular course of medical treatment. Use of the practice guidelines and this resource are voluntary.
e practice guidelines and additional information are available at www.asco.org/breast-cancer-
guidelines. Copyright © 2020 by American Society of Clinical Oncolog y. All rights reserved.
ASCOMAL02203
Abbreviations
AI, aromatase inhibitor; ASCO, American Society of Clinical Oncolog y; CDK, cyclin-
dependent kinase; GnRH, gonadotropin releasing hormone; HER2, human epidermal growth
factor receptor 2; MRI, magnetic resonance imaging ; PDL-1, programmed death-ligand 1
Source
Michael J. Hassett, MD, MPH; Mark R. Somerfield, PhD; Elisha R. Baker, PhD; Fatima
Cardoso, MD; Kari J. Kansal, MD; Dylan C. Kwait, MD; Jennifer K. Plichta, MD, MS;
Charité Ricker, MS, CGC; Anna Roshal, MD; Kathryn J. Ruddy, MD, MPH; Joshua D.
Safer, MD; Catherine Van Poznak, MD; Rachel L. Yung, MD; and Sharon H. Giordano, MD,
MPH. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol. 2020 Feb 14
doi: 10.1200/JCO.19.03120.
ASCO believes that cancer clinical trials are vital to inform medical decisions and
improve cancer care and that all patients should have the opportunity to participate.
Additional information, which may include data supplements, slide sets, and
other clinical tools and resources, is available at www.asco.org/breast-cancer-guidelines.
Recommendation Grading
Type Benefit/harm Evidence Quality
Strength of
Recommendation
EB Evidence-
based
B Benefits
outweigh harms
H High Strong
FC
Formal
consensus
H Harms outweigh
benefits
I Intermediate Moderate
IC Informal
consensus
B/H Relative balance
of benefits and
harms
L Low Weak
U Benefits/harms
ratio uncertain
Ins Insufficient